<DOC>
	<DOCNO>NCT00569686</DOCNO>
	<brief_summary>Sixty patient mild-to-moderate PAD ( ABI 0.4-0.9 ) hypertriglyceridemia ( &gt; 200 mg/dl ) already treat statin image baseline randomize Lovaza placebo 12 month . MR image repeated end 12-month period . We hypothesize treatment hypertriglyceridemia patient PAD Lovaza reduce atherosclerotic plaque volume superficial femoral artery ( SFA ) 2 % 1 year compare placebo . Secondary aim show improved plaque characteristic ( thicken fibrous cap , reduce lipid-rich necrotic core , improve exercise calf muscle perfusion use first-pass contrast enhance MRI improve exercise treadmill performance Lovaza compare match placebo .</brief_summary>
	<brief_title>Lovaza Therapy Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Male female , ethnicity , age 5575 Mild moderate PAD ( ankle brachial index ( ABI ) 0.40.9 either limb ) Symptomatic intermittent claudication either limbs Hyperlipidemia treat HMGCoA reductase inhibition persistent hypertriglyceridemia ( triglyceride &gt; 200 ) . Patients critical limb ischemia Moderate severe chronic kidney disease ( require hemodialysis glomerular filtration rate ( GFR ) &lt; 45 ml/min ) Contraindication MRI ( pacemaker , defibrillator , intraocular metal , certain intracerebral aneurysm clip , etc . ) Claustrophobia Known allergy gadolinium chelate Patients iron storage disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>PAD</keyword>
	<keyword>peripheral artery disease</keyword>
</DOC>